Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 37, 2002 - Issue 9
Submit an article Journal homepage
85
Views
57
CrossRef citations to date
0
Altmetric
Research Article

Pyoderma Gangrenosum Associated with Crohn Disease: Effect of TNF- α Blockade with Infliximab

T. Ljung
,
M. Staun
,
O. Grove
,
O. Fausa
,
M. H. Vatn
&
P. M. Hellström
Pages 1108-1110 | Published online: 08 Jul 2009

Citations (57)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Shana Rakowsky, Konstantinos Papamichael & Adam S. Cheifetz. (2022) Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 16:3, pages 235-249.
Read now
Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings & Alex G. Ortega-Loayza. (2019) Biologic and small-molecule medications in the management of pyoderma gangrenosum. Journal of Dermatological Treatment 30:3, pages 264-276.
Read now
Zsuzsanna Vegh, Zsuzsanna Kurti, Lorant Gonczi, Petra Anna Golovics, Barbara Dorottya Lovasz, Istvan Szita, Mihaly Balogh, Tunde Pandur, Stephan R Vavricka, Gerhard Rogler, Laszlo Lakatos & Peter Laszlo Lakatos. (2016) Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 51:7, pages 848-854.
Read now
Raj Patel, John M Cafardi, Nital Patel, Naveed Sami & Jennifer A Cafardi. (2011) Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opinion on Biological Therapy 11:10, pages 1341-1359.
Read now
Masahiro Tada, Takeshi Nakanishi, Chika Hirata, Tadashi Okano, Yuko Sugioka, Shigeyuki Wakitani, Hiroaki Nakamura & Tatsuya Koike. (2010) Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis. Modern Rheumatology 20:6, pages 598-601.
Read now
Christian Bunte, Jutta Popp-Habeler, Paul Mischer, Herwig Tuppy, Alexander Haidenthaler, Peter Knoflach & Andreas Kirchgatterer. (2008) Concomitant manifestation of pyoderma gangrenosum and colorectal carcinoma. Scandinavian Journal of Gastroenterology 43:6, pages 756-758.
Read now

Articles from other publishers (51)

Philip J. Hampton & Stephanie Ball. 2024. Rook's Textbook of Dermatology. Rook's Textbook of Dermatology 1 27 .
Magdalena Łyko, Anna Ryguła, Michał Kowalski, Julia Karska & Alina Jankowska-Konsur. (2024) The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives. International Journal of Molecular Sciences 25:4, pages 2440.
Crossref
Lucas Guillo, Ferdinando D’Amico, Mélanie Serrero, Karine Angioi, Damien Loeuille, Antonio Costanzo, Silvio Danese & Laurent Peyrin‐Biroulet. (2020) Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. United European Gastroenterology Journal 8:9, pages 1013-1030.
Crossref
Quoc-Bao D. Nguyen, Caroline T. Starling & Adelaide A. Hebert. (2020) The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders. Pediatric Drugs 22:3, pages 311-319.
Crossref
Hakim Ben Abdallah, Karsten Fogh & Rikke Bech. (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review. International Wound Journal 16:2, pages 511-521.
Crossref
A.C.R. Partridge, J.W. Bai, C.F. Rosen, S.R. Walsh, W.P. Gulliver & P. Fleming. (2018) Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. British Journal of Dermatology.
Crossref
Ladan Afifi, Isabelle M. Sanchez, Matthew M. Wallace, Sara F. Braswell, Alex G. Ortega-Loayza & Kanade Shinkai. (2018) Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. Journal of the American Academy of Dermatology 78:6, pages 1195-1204.e1.
Crossref
Xinying Wang & Bo Shen. (2018) Management of Crohn’s Disease and Complications in Patients With Ostomies. Inflammatory Bowel Diseases 24:6, pages 1167-1184.
Crossref
Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard & Robert S. Kirsner. (2017) Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology 18:3, pages 355-372.
Crossref
Aldana S. Vacas, Ana C. Torre, María L. Bollea‐Garlatti, Fernando Warley & Ricardo L. Galimberti. (2017) Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. International Journal of Dermatology 56:4, pages 386-391.
Crossref
Anthony D. Ormerod & Philip J. Hampton. 2016. Rook's Textbook of Dermatology, Ninth Edition. Rook's Textbook of Dermatology, Ninth Edition 1 23 .
Ricardo Luis Galimberti, Aldana Soledad Vacas, María Luz Bollea Garlatti & Ana Clara Torre. (2016) The role of interleukin-1β in pyoderma gangrenosum. JAAD Case Reports 2:5, pages 366-368.
Crossref
Stephan R. Vavricka, Alain Schoepfer, Michael Scharl, Peter L. Lakatos, Alexander Navarini & Gerhard Rogler. (2015) Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 21:8, pages 1982-1992.
Crossref
E.M. DeFilippis, S.R. Feldman & W.W. Huang. (2015) The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. British Journal of Dermatology 172:6, pages 1487-1497.
Crossref
Hiroaki HAYASHI, Chiaki KUWABARA, Kenichi TARUMI, Eiichi MAKINO & Wataru FUJIMOTO. (2011) Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease. The Journal of Dermatology 39:6, pages 576-578.
Crossref
Vincent Falanga, Christina Lindholm, Polly A. Carson, Jaymie Panuncialman, Lisa Mamakos, Tiziana N. Lotti & Jane K. Falanga. 2012. Text Atlas of Wound Management. Text Atlas of Wound Management 207 218 .
Joni Mazza, Anthony Rossi & Jeffrey M. Weinberg. (2010) Innovative Uses of Tumor Necrosis Factor α Inhibitors. Dermatologic Clinics 28:3, pages 559-575.
Crossref
Robert S. Kirsner. (2010) Biological Agents for Chronic Wounds. American Journal of Clinical Dermatology 11, pages 23-25.
Crossref
Jeremiah Miller, Brad A. Yentzer, Adele Clark, Joseph L. Jorizzo & Steven R. Feldman. (2010) Pyoderma gangrenosum: A review and update on new therapies. Journal of the American Academy of Dermatology 62:4, pages 646-654.
Crossref
Gert Van Assche, Axel Dignass, Walter Reinisch, C. Janneke van der Woude, Andreas Sturm, Martine De Vos, Mario Guslandi, Bas Oldenburg, Iris Dotan, Philippe Marteau, Alessandro Ardizzone, Daniel C. Baumgart, Geert D'Haens, Paolo Gionchetti, Francisco Portela, Boris Vucelic, Johan Söderholm, Johanna Escher, Sibylle Koletzko, Kaija-Leena Kolho, Milan Lukas, Christian Mottet, Herbert Tilg, Séverine Vermeire, Frank Carbonnel, Andrew Cole, Gottfried Novacek, Max Reinshagen, Epameinondas Tsianos, Klaus Herrlinger, Bas Oldenburg, Yoram Bouhnik, Ralf Kiesslich, Eduard Stange, Simon Travis & James Lindsay. (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn's and Colitis 4:1, pages 63-101.
Crossref
Luciano Alessandroni & Andrea Scotti. 2010. Crohn’s Disease. Crohn’s Disease 221 226 .
Vimal Prajapati, Jeremy Man & Alain Brassard. (2009) Pyoderma Gangrenosum: Common Pitfalls in Management and a Stepwise, Evidence-Based, Therapeutic Approach. Journal of Cutaneous Medicine and Surgery 13:3_suppl, pages S2-S11.
Crossref
Eva Zold, Arpad Nagy, Katalin Devenyi, Margit Zeher & Zsolt Barta. (2009) Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone. World Journal of Gastroenterology 15:18, pages 2293.
Crossref
Fatih Ermis, Sadakat Ozdil, Filiz Akyüz, Binnur Pinarbasi & Zeynel Mungan. (2008) Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis. Inflammatory Bowel Diseases 14:11, pages 1611-1613.
Crossref
Susan Yoong, Gillian Dunne, Janette Cochrane, Bernard Lee & Jack Lee. (2008) Vacuum-Assisted Closure for the Treatment of Parastomal Skin Necrosis: A Novel Approach to an Unusual Complication. Report of a Case. Diseases of the Colon & Rectum 51:10, pages 1577-1579.
Crossref
B. Díaz-Ley, G. Guhl & J. Fernández-Herrera. (2007) Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab. Actas Dermo-Sifiliográficas 98:10, pages 657-678.
Crossref
K. Vandevyvere, F. P. Luyten, P. Verschueren, R. Lories, S. Segaert & R. Westhovens. (2007) Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clinical Rheumatology 26:12, pages 2205-2206.
Crossref
Arthur Barrie & Miguel Regueiro. (2007) Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflammatory Bowel Diseases 13:11, pages 1424-1429.
Crossref
Carlos A. Charles, Argentina Leon, Meggan R. Banta & Robert S. Kirsner. (2007) Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. International Journal of Dermatology 46:10, pages 1095-1099.
Crossref
Benjamin Siemanowski & Miguel Regueiro. (2007) Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Current Treatment Options in Gastroenterology 10:3, pages 178-184.
Crossref
Javier P. Gisbert & Fernando Gomollón. (2007) Errores frecuentes en el manejo del paciente grave con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 30:5, pages 294-314.
Crossref
Ziad Reguia??Florent Grange. (2007) The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease. American Journal of Clinical Dermatology 8:2, pages 67-77.
Crossref
Julia E. Graves, Kara Nunley & Michael P. Heffernan. (2007) Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). Journal of the American Academy of Dermatology 56:1, pages e55-e79.
Crossref
B. Díaz-Ley, G. Guhl & J. Fernández-Herrera. (2007) Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 1: Infliximab and Adalimumab. Actas Dermo-Sifiliográficas (English Edition) 98:10, pages 657-678.
Crossref
Mary Jo. J. Kerns, Julia E. Graves, David I. Smith & Michael P. Heffernan. (2006) Off-Label Uses of Biologic Agents in Dermatology: A 2006 Update. Seminars in Cutaneous Medicine and Surgery 25:4, pages 226-240.
Crossref
Arthur Barrie & Scott Plevy. (2006) Treatment of Immune-Mediated Extraintestinal Manifestations of Inflammatory Bowel Disease with Infliximab. Gastroenterology Clinics of North America 35:4, pages 883-893.
Crossref
Brian J. Nickoloff & Seth R. Stevens. (2006) What have we learned in dermatology from the biologic therapies?. Journal of the American Academy of Dermatology 54:3, pages S143-S151.
Crossref
Mark Lebwohl & Elizabeth H.Z. Thompson. (2006) Introduction. Journal of the American Academy of Dermatology 54:3, pages S65-S66.
Crossref
Noah Scheinfeld. 2006. TNF-alpha Inhibitors. TNF-alpha Inhibitors 83 99 .
Andrew F. Alexis & Bruce E. Strober. (2016) Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal of Cutaneous Medicine and Surgery 9:6, pages 296-302.
Crossref
Andrew F. Alexis & Bruce E. Strober. (2006) Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal of Cutaneous Medicine and Surgery 9:6, pages 296-302.
Crossref
Sharareh Ahmadi & Frank C. Powell. (2005) Pyoderma gangrenosum: uncommon presentations. Clinics in Dermatology 23:6, pages 612-620.
Crossref
L B Trost & J K McDonnell. (2005) Important cutaneous manifestations of inflammatory bowel disease. Postgraduate Medical Journal 81:959, pages 580-585.
Crossref
Jörg Reichrath, Guido Bens, Anette Bonowitz & Wolfgang Tilgen. (2005) Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. Journal of the American Academy of Dermatology 53:2, pages 273-283.
Crossref
Dorothee S. Stichweh, Marilynn Punaro & Virginia Pascual. (2005) Dramatic Improvement of Pyoderma Gangrenosum with Infliximab in a Patient with PAPA Syndrome. Pediatric Dermatology 22:3, pages 262-265.
Crossref
Edward V. LoftusJrJr. (2004) Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Current Gastroenterology Reports 6:6, pages 506-513.
Crossref
Angela Ehling, Sigrid Karrer, Frank Klebl, Andreas Schäffler & Ulf Müller‐Ladner. (2004) Therapeutic management of pyoderma gangrenosum. Arthritis & Rheumatism 50:10, pages 3076-3084.
Crossref
Perrine Cocq, Yazdan Yazdanpannah, Bruno Mesnard & Jean-Frédéric Colombel. (2004) Indications, effets indésirables des anti-TNF et mesures préventives. Gastroentérologie Clinique et Biologique 28:5, pages 61-69.
Crossref
Benjamin Lebwohl & Allen N Sapadin. (2003) Infliximab for the treatment of hidradenitis suppurativa. Journal of the American Academy of Dermatology 49:5, pages 275-276.
Crossref
Laszlo Lakatos. (2003) Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: Results of a 25-year follow-up study. World Journal of Gastroenterology 9:10, pages 2300.
Crossref
Samuel L Gettler, Marti J Rothe, Caron Grin & Jane M Grant-Kels. (2003) Optimal Treatment of Pyoderma Gangrenosum. American Journal of Clinical Dermatology 4:9, pages 597-608.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.